NEVVI Medicare utilization intelligence

← back

RIAZ, WASIFM.D NPI 1497929319 Clinician

Hematology-Oncology · SEBRING, FL

Specialty Hematology-Oncology — from billed Medicare claims
In practice about 25 years since medical school (class of 2001, self-reported to CMS)
Location SEBRING, FL · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 65 codes billed · 225,690 disclosed services (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20192026
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC
2019–2026

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2022-08

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Unlock to see the figure.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J1756 Injection, iron sucrose, 1 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
J0897 Injection, denosumab, 1 mg
J9271 Injection, pembrolizumab, 1 mg
J0185 Injection, aprepitant, 1 mg
J1442 Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram
Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
J9267 Injection, paclitaxel, 1 mg
J1434 Injection, fosaprepitant (focinvez), 1 mg
J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units
J9173 Injection, durvalumab, 10 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
36415 Insertion of needle into vein for collection of blood sample
Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
J2469 Injection, palonosetron hcl, 25 mcg
Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units
96372 Injection of drug or substance under skin or into muscle
96375 Injection of additional new drug or substance into vein
J2919 Injection, methylprednisolone sodium succinate, 5 mg
J2405 Injection, ondansetron hydrochloride, per 1 mg
J1750 Injection, iron dextran, 50 mg
96413 Administration of chemotherapy into vein, 1 hour or less
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
J3489 Injection, zoledronic acid, 1 mg
J1200 Injection, diphenhydramine hcl, up to 50 mg
J9045 Injection, carboplatin, 50 mg
Q5127 Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
96415 Administration of chemotherapy into vein, each additional hour
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
96417 Administration of additional new drug or substance into vein, 1 hour or less
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
J3475 Injection, magnesium sulfate, per 500 mg
96374 Injection of drug or substance into vein
J7030 Infusion, normal saline solution , 1000 cc
96361 Infusion into a vein for hydration, each additional hour
96411 Administration of additional new drug or substance into vein using push technique
J1954 Injection, leuprolide acetate for depot suspension (cipla), 7.5 mg
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
96360 Infusion into a vein for hydration, 31-60 minutes
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
81003 Automated urinalysis test
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
J2920 Injection, methylprednisolone sodium succinate, up to 40 mg
99497 Advance care planning, first 30 minutes
99211 Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional
99195 Drawing of blood for a medical problem
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes
99496 Transitional care management services for problem of high complexity
99203 New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.